Article thumbnail
Location of Repository

Nanoparticle-Mediated Expression of an Angiogenic Inhibitor Ameliorates Ischemia-Induced Retinal Neovascularization and Diabetes-Induced Retinal Vascular Leakage

By Kyoungmin Park, Ying Chen, Yang Hu, Aaron S. Mayo, Uday B. Kompella, Richard Longeras and Jian-xing Ma
Topics: Original Article
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:2712783
Provided by: PubMed Central

Suggested articles

Citations

  1. A central role for inflammation in the pathogenesis of diabetic retinopathy.
  2. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
  3. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa.
  4. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents.
  5. (2007). Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res
  6. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy.
  7. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;2(Suppl.): S253–S262
  8. (1998). Diabetic retinopathy. Diabetes Care
  9. DNA nanoparticles and development of DNA delivery vehicles for gene therapy.
  10. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.
  11. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med (Maywood)
  12. (2003). Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther
  13. Gene therapy restores vision in a canine model of childhood blindness.
  14. (2003). Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol
  15. Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy.
  16. (2002). In vitro characterization of a spontaneously immortalized human Muller cell line (MIO-M1). Invest Ophthalmol Vis Sci
  17. (2009). Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.
  18. (1997). Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth.
  19. (2009). kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.
  20. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.
  21. (1994). Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci
  22. Pathogenesis of retinopathy of prematurity.
  23. (2002). PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med
  24. Pigment epitheliumderived factor (PEDF) is an endogenous anti-inflammatory factor.
  25. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes.
  26. Rapid endolysosomal escape of poly (D, L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery.
  27. (1999). Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulinlike growth factor-1 receptor.
  28. (2000). Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl
  29. (2002). Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin Drug Saf
  30. Sensitive blood-retinal barrier breakdown quantitation using Evans blue.
  31. (2006). Surface-modified biodegradable microspheres for DNA vaccine delivery. Methods Mol Med
  32. (2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther
  33. Synthetic DNA delivery systems.
  34. Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes.
  35. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
  36. The effect of angiostatin on vascular leakage and VEGF expression in rat retina.
  37. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.
  38. (1997). Vascular endothelial growth factor and ocular neovascularization.
  39. (1999). Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors.
  40. (1997). Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes
  41. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.